ACUT

AccuStem Sciences, Inc. operates as a life science firm committed to improving the outlook for individuals battling cancer. Its primary innovation is the StemPrintER technology, an advanced multi-gene prognostic assay designed to predict the likelihood of recurrence for patients with Endocrine receptor-positive /HER2- breast cancer. The company also offers Spare, a related diagnostic tool that expands upon StemPrintER by incorporating two additional clinical markers. AccuStem Sciences, Inc. is based in New York, New York.